Johnson & Johnson sued the Biden administration over Medicare's new powers to slash drug prices, making it the third pharmaceutical company to challenge the controversial provision of the Inflation ...

A federal judge in New Jersey rejected Johnson & Johnson's and Bristol Myers Squibb's legal challenges to the Biden administration's Medicare drug-price negotiations, ruling that the program is ...

Johnson & Johnson (NYSE:JNJ) and Bristol Myers Squibb (NYSE:BMY) have become the latest industry participants to lose legal challenges against the Medicare drug price negotiation program, a major ...

There might just be a silver lining for Johnson & Johnson in the FDA's recent approval of Amgen’s Stelara biosimilar. That’s because the coming entry of a cheaper copycat presents J&J with an ...